Blood and Marrow Transplant Program, Moffitt Cancer Center, Tampa, FL 33612, USA.
Cancer Control. 2012 Jul;19(3):175-86. doi: 10.1177/107327481201900302.
B-cell lymphoma comprises the majority of non-Hodgkin lymphomas worldwide. Hematopoietic cell transplantation (HCT) is used for patients with high-risk, relapsed, or refractory B-cell lymphoma.
The current medical literature and the results of recently published trials were reviewed to provide an update on the most common indications for HCT in B-cell lymphoma.
Autologous HCT has evolving and new roles in the treatment of patients with high-risk diffuse large B-cell cell lymphoma, mantle cell lymphoma, and HIV-related lymphoma. Reduced-intensity conditioning has largely replaced older myeloablative conditioning regimens, making allogeneic transplantation safer for more patients with lymphoma.
The indication and timing of HCT depend on the patient's histology, age, and response to previous therapies. HCT is an essential component in the armamentarium to treat B-cell lymphoma.
B 细胞淋巴瘤占全球非霍奇金淋巴瘤的大多数。造血细胞移植（HCT）用于治疗高危、复发或难治性 B 细胞淋巴瘤患者。
本研究回顾了当前的医学文献和最近发表的试验结果，以提供 B 细胞淋巴瘤中 HCT 最常见适应证的最新信息。
自体 HCT 在治疗高危弥漫性大 B 细胞淋巴瘤、套细胞淋巴瘤和 HIV 相关淋巴瘤患者方面具有不断发展和新的作用。减强度预处理已在很大程度上取代了旧的清髓性预处理方案，使更多淋巴瘤患者能够接受更安全的异基因移植。
HCT 的适应证和时机取决于患者的组织学、年龄以及对先前治疗的反应。HCT 是治疗 B 细胞淋巴瘤的重要手段之一。
